Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy

INTRODUCTION: Spleen tyrosine kinase (SYK) is a key integrator of intracellular signals triggered by activated immunoreceptors, including Bcell receptors (BCR) and Fc receptors, which are important for the development and function of lymphoid cells. Given the clinical efficacy of Bcell depletion in...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Cheng, Hsu, Jonathan, Kim, Yong, Hu, Dong-Qing, Xu, Daigen, Zhang, Jun, Pashine, Achal, Menke, John, Whittard, Toni, Romero, Natasha, Truitt, Theresa, Slade, Michelle, Lukacs, Christine, Hermann, Johannes, Zhou, Mingyan, Lucas, Matthew, Narula, Satwant, DeMartino, Julie, Tan, Seng-Lai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978604/
https://www.ncbi.nlm.nih.gov/pubmed/24286216
http://dx.doi.org/10.1186/ar4329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978604/
https://www.ncbi.nlm.nih.gov/pubmed/24286216
http://dx.doi.org/10.1186/ar4329

Ejemplares similares